Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SCH 900121
Commercial NOMAC-E2 · 1 trial · 1 indication
Bioequivalence for NOMAC and E2 were tested on the primary PK parameters: Cmax, AUC(infinity), and AUClast for NOMAC; and baseline adjusted AUC72 and Cmax for E2. Blood samples for pharmacokinetic (PK) evaluation of NOMAC were collected at predose (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 144 hours postdose Day 1.
Bioequivalence for NOMAC and E2 were tested on the primary PK parameters: Cmax, AUC(infinity), and AUClast for NOMAC; and baseline adjusted AUC72 and Cmax for E2. Blood samples for PK evaluation of E2 were collected predose (-1, -0.5, and 0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose Day 1; multiple predose samples were needed to correct for endogenous levels.
Bioequivalence for NOMAC and E2 were tested on the primary PK parameters: Cmax, AUC(infinity), and AUClast for NOMAC; and baseline adjusted AUC72 and Cmax for E2. AUClast is the AUC from time 0 to the time of the final quantifiable sample. AUC infinity is the AUC from time 0 to infinity. Blood samples for PK evaluation of NOMAC were collected at predose (0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, 96, and 144 hours postdose Day 1.
Bioequivalence for NOMAC and E2 were tested on the primary PK parameters: Cmax, AUC(infinity), and AUClast for NOMAC; and baseline adjusted AUC72 and Cmax for E2. AUC72 is the AUC from time 0 to 72 hours. Blood samples for PK evaluation of E2 were collected predose (-1, -0.5, and 0 hour) and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose Day 1; multiple predose samples were needed to correct for endogenous levels.
| Arm | Type | Description |
|---|---|---|
| Commercial NOMAC-E2, Part 1 | EXPERIMENTAL | Participants received a single oral dose of the NOMAC-E2 fixed-dose combination commercial tablet (2.5 mg NOMAC/1.5 mg E2), either on the first day of Period 1 and Period 3 (for participants randomized to Sequence 1) or on the first day of Period 2 and Period 4 (for participants randomized to Sequence 2). Participants in Part 1 were from "Site 1". |
| Phase 3 NOMAC-E2, Part 1 | ACTIVE_COMPARATOR | Participants received a single oral dose of the NOMAC-E2 fixed-dose combination tablet (2.5 mg NOMAC/1.5 mg E2) from the Phase 3 clinical trial program ("Batch A"), either on the first day of Period 2 and Period 4 (for participants randomized to Sequence 1) or on the first day of Period 1 and Period 3 (for participants randomized to Sequence 2). Participants in Part 1 were from "Site 1". |
| Commercial NOMAC-E2, Part 2 | EXPERIMENTAL | Participants received a single oral dose of the NOMAC-E2 fixed-dose combination commercial tablet (2.5 mg NOMAC/1.5 mg E2), either on the first day of Period 1 and Period 3 (for participants randomized to Sequence 1) or on the first day of Period 2 and Period 4 (for participants randomized to Sequence 2). Participants in Part 2 were from "Site 2". |
| Phase 3 NOMAC-E2, Part 2 | ACTIVE_COMPARATOR | Participants received a single oral dose of the NOMAC-E2 fixed-dose combination tablet (2.5 mg NOMAC/1.5 mg E2) from the Phase 3 clinical trial program ("Batch B"), either on the first day of Period 2 and Period 4 (for participants randomized to Sequence 1) or on the first day of Period 1 and Period 3 (for participants randomized to Sequence 2). Participants in Part 2 were from "Site 2". |
| Name | Type | Description |
|---|---|---|
| Commercial NOMAC-E2 | DRUG | 1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination commercial tablet orally in the morning on Day 1 for all periods |
| Phase 3 NOMAC-E2 "Batch A" | DRUG | 1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program ("Batch A") orally in the morning on Day 1 for all periods |
| Phase 3 NOMAC-E2 "Batch B" | DRUG | 1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program ("Batch B") orally in the morning on Day 1 for all periods |
Key Inclusion Criteria: * Healthy postmenopausal females between the ages of 45 and 70 years, inclusive, having a Body Mass Index (BMI) between 18 and 32, inclusive; * Free of any clinically significant disease that would interfere with the study evaluations. Key Exclusion Criteria: * Any surgica...
Commercial NOMAC-E2 is a small molecule combination product containing nomegestrol acetate (NOMAC) and estradiol (E2). It was evaluated in a Phase 1 bioequivalence study comparing commercial batches of NOMAC-E2 tablets against Phase 3 pivotal clinical batches. The study enrolled healthy postmenopausal females.
Commercial NOMAC-E2 is developed by Organon & Co., which trades under the ticker OGN. Organon sponsored the Phase 1 bioequivalence trial of the product.
Commercial NOMAC-E2 has been studied in a Phase 1 clinical trial. The single registered trial, NCT01345786, is completed. The program is at the Phase 1 stage of clinical development.
Commercial NOMAC-E2 has been studied in one clinical trial, NCT01345786, titled Bioequivalence of Nomegestrol Acetate (NOMAC) and Estradiol (E2) in Commercial Versus Phase 3 Pivotal Clinical Batches of NOMAC-E2 Tablets. The trial is completed, enrolled 158 participants, and was active controlled and randomized.
The NCT01345786 trial was a Phase 1, randomized, active controlled bioequivalence study of Commercial NOMAC-E2 tablets versus Phase 3 pivotal clinical batches. It enrolled 158 healthy postmenopausal females aged 45 years and older. The trial is completed.